Consistent with Cardium's overall business strategy and concurrent with the conduct of the MATRIX clinical trial, the Company expects to pursue strategic discussions with respect to potential development, marketing and sales partnerships for Excellarate. With continued clinical advancement, Excellarate offers the potential to be commercially available in late 2011 or early 2012.
Cardium Biologics, Inc.
Cardium's Generx(TM) product candidate (alferminogene tadenovec, Ad5FGF-4) is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. The current focus of Cardium's biologics program is to advance the Excellarate product candidate though its current Phase 2b MATRIX study. Following the near-term completion of enrollment in the MATRIX study, Cardium expects to be in a position to devote additional resources toward the Generx program, including a potentially reformulated composition that would allow the Generx study product to be stored under more convenient temperature conditions.
Cardium's pre-clinical research at Emory University for its product
candidate, Corgentin(TM) (Ad5IGF-1), is continuing with the support of an
NIH Small Business Innovation Research (SBIR) grant, to further establish
the therapeutic potential of Corgentin to preserve heart tissue and cardiac
function following a heart attack (acute myocardial infarction). Corgentin
is a DNA therapeutic bas
|SOURCE Cardium Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved